11/30/2005 10731290.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HOME' AT 14:00:51 ON 30 NOV 2005
FILE 'HOME' ENTERED AT 14:00:51 ON 30 NOV 2005

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 14:01:06 ON 30 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2005 HIGHEST RN 868827-82-1
DICTIONARY FILE UPDATES: 28 NOV 2005 HIGHEST RN 868827-82-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *

* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10731290.str





chain nodes :
14 15
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13
chain bonds :
11-15 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-10 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
5-6 5-9 9-10 11-15 12-14
exact bonds :
7-10 8-9 8-13 10-11 11-12 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-7 6-7
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 14:01:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       28 TO ITERATE

100.0% PROCESSED       28 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          243 TO      877
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 14:01:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      556 TO ITERATE

100.0% PROCESSED      556 ITERATIONS                               12 ANSWERS
SEARCH TIME: 00.00.01

L3            12 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     161.33     161.96

FILE 'HCAPLUS' ENTERED AT 14:01:36 ON 30 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Nov 2005 VOL 143 ISS 23
FILE LAST UPDATED: 29 Nov 2005 (20051129/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 1 L3

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:515514 HCAPLUS
DOCUMENT NUMBER: 141:71529
TITLE: Preparation of substituted dihydropyranoindole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
INVENTOR(S): Elokdah, Hassan Mahmoud; Li, David Zenan
PATENT ASSIGNEE(S): Wyeth, USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052893	A2	20040624	WO 2003-US38932	20031209
WO 2004052893	A3	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509242	AA	20040624	CA 2003-2509242	20031209
US 2005113436	A1	20050526	US 2003-731290	20031209
EP 1569639	A2	20050907	EP 2003-812845	20031209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016586	A	20051011	BR 2003-16586	20031209
PRIORITY APPLN. INFO.:			US 2002-432327P P	20021210
			WO 2003-US38932 W	20031209

OTHER SOURCE(S): MARPAT 141:71529
GI



I



II

AB The title compds. [I and II; X = H, alkali metal or a basic amine moiety; R1 = alkyl, cycloalkyl, CH2(cycloalkyl), pyridinyl, CH2(pyridinyl), Ph, CH2Ph, the rings of these groups being optionally substituted; R2 = H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, CH2(cycloalkyl), NH2, NO2; R3 = Ph, CH2Ph, OCH2Ph, pyridinyl, CH2(pyridinyl), etc., with the rings of these groups being optionally substituted] or a pharmaceutically acceptable salt or ester forms thereof, useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis, were prepared E.g., a 7-step synthesis of 9-(4-methylbenzyl)-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-b]indole-3,4-dione II, starting from Et 5-bromo-1H-indole-2-carboxylate and 4-methylbenzyl bromide, was given. The compound II showed IC50 of 2.3 μM against human PAI-1. The pharmaceutical composition comprising the compound I is claimed.

IT **711010-50-3P 711010-53-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted dihydropyranoindole-3,4-dione derivs. as inhibitors of plasminogen activator inhibitor-1 (PAI-1))

RN 711010-50-3 HCAPLUS
CN Pyrano[3,4-b]indole-3,4-dione, 6-(4-chlorophenyl)-1,9-dihydro-9-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 711010-53-6 HCAPLUS
CN Pyrano[3,4-b]indole-3,4-dione, 6-[1,1'-biphenyl]-4-yl-1,9-dihydro-9-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **711010-42-3P 711010-43-4P 711010-44-5P**
711010-45-6P 711010-46-7P 711010-47-8P
711010-48-9P 711010-49-0P 711010-52-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted dihydropyranoindole-3,4-dione derivs. as inhibitors of plasminogen activator inhibitor-1 (PAI-1))

RN 711010-42-3 HCAPLUS
CN Pyrano[3,4-b]indole-3,4-dione, 1,9-dihydro-9-[(4-methylphenyl)methyl]-6-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 711010-43-4 HCAPLUS
CN Pyrano[3,4-b]indole-3,4-dione, 1,9-dihydro-9-(phenylmethyl)-6-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 711010-44-5 HCAPLUS
CN Pyrano[3,4-b]indole-3,4-dione, 1,9-dihydro-6-(3-methylphenyl)-9-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 711010-45-6 HCAPLUS
CN Pyrano[3,4-b]indole-3,4-dione, 9-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,9-dihydro-6-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 711010-46-7 HCAPLUS
CN Pyrano[3,4-b]indole-3,4-dione, 1,9-dihydro-9-[(4-methylphenyl)methyl]-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 711010-47-8 HCAPLUS
CN Pyrano[3,4-b]indole-3,4-dione, 1,9-dihydro-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 711010-48-9 HCAPLUS
CN Pyrano[3,4-b]indole-3,4-dione, 9-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,9-dihydro-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 711010-49-0 HCAPLUS
CN Pyrano[3,4-b]indole-3,4-dione, 9-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,9-dihydro-6-hydroxy- (9CI) (CA INDEX NAME)



RN 711010-52-5 HCAPLUS
CN Pyrano[3,4-b]indole-3,4-dione, 1,9-dihydro-6-(3-methylphenyl)-9-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **711010-72-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted dihydropyranoindole-3,4-dione derivs. as inhibitors of plasminogen activator inhibitor-1 (PAI-1))
RN 711010-72-9 HCAPLUS
CN Pyrano[3,4-b]indole-3,4-dione, 9-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,9-dihydro-6-methoxy- (9CI) (CA INDEX NAME)



```
=> FIL REGISTRY
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    14.74     176.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -0.73      -0.73

FILE 'REGISTRY' ENTERED AT 14:04:07 ON 30 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 NOV 2005  HIGHEST RN 868827-82-1
DICTIONARY FILE UPDATES:  28 NOV 2005  HIGHEST RN 868827-82-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************************
*                                                                       *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                       *
*************************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10731290a.str
```



chain nodes :
14 15
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 17 18 19 20 21 22
chain bonds :
2-21 11-15 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-10 8-9 8-13 9-10 10-11 11-12 12-13
17-18 17-22 18-19 19-20 20-21 21-22
exact/norm bonds :
5-6 5-9 9-10 11-15 12-14
exact bonds :
2-21 7-10 8-9 8-13 10-11 11-12 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-7 6-7 17-18 17-22 18-19 19-20 20-21 21-22
isolated ring systems :
containing 1 : 17 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 17:Atom 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l5
SAMPLE SEARCH INITIATED 14:04:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        2 TO ITERATE

100.0% PROCESSED         2 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:             2 TO      124
PROJECTED ANSWERS:                0 TO        0

L6             0 SEA SSS SAM L5

=> s l5 sss full
FULL SEARCH INITIATED 14:04:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       22 TO ITERATE

100.0% PROCESSED        22 ITERATIONS                               0 ANSWERS
SEARCH TIME: 00.00.01

L7             0 SEA SSS FUL L5

=>
Uploading C:\Program Files\Stnexp\Queries\10731290b.str
```





```
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13
```

ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-9 6-7 7-10 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
5-6 5-9 9-10
exact bonds :
7-10 8-9 8-13 10-11 11-12 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-7 6-7
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom

L8 STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l8
SAMPLE SEARCH INITIATED 14:05:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 456 TO ITERATE

100.0% PROCESSED 456 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7839 TO 10401
PROJECTED ANSWERS: 1014 TO 2066

L9 50 SEA SSS SAM L8

=> s l8 sss full
FULL SEARCH INITIATED 14:05:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 8303 TO ITERATE

100.0% PROCESSED 8303 ITERATIONS 1610 ANSWERS
SEARCH TIME: 00.00.01

L10 1610 SEA SSS FUL L8

=>
Uploading C:\Program Files\Stnexp\Queries\10731290c.str





chain nodes :
11 12 13 14 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
8-16 9-11 11-12 11-15 12-13 12-14 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-8 6-7 7-9 8-9
exact/norm bonds :
5-6 5-8 11-15 12-13 12-14 16-17
exact bonds :
7-9 8-9 8-16 9-11 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-7 6-7
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS

L11 STRUCTURE UPLOADED

=> d l11
L11 HAS NO ANSWERS
L11 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l11
SAMPLE SEARCH INITIATED 14:08:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       24 TO ITERATE

100.0% PROCESSED       24 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          187 TO      773
PROJECTED ANSWERS:               0 TO        0

L12           0 SEA SSS SAM L11

=> s l11 sss full
FULL SEARCH INITIATED 14:08:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      459 TO ITERATE

100.0% PROCESSED      459 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

L13           0 SEA SSS FUL L11

=>
=> d his

     (FILE 'HOME' ENTERED AT 13:58:49 ON 30 NOV 2005)

     FILE 'REGISTRY' ENTERED AT 14:01:06 ON 30 NOV 2005
L1              STRUCTURE UPLOADED
L2            0 S L1
L3           12 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 14:01:36 ON 30 NOV 2005
L4            1 S L3

     FILE 'REGISTRY' ENTERED AT 14:04:07 ON 30 NOV 2005
L5              STRUCTURE UPLOADED
L6            0 S L5
L7            0 S L5 SSS FULL
L8              STRUCTURE UPLOADED
L9           50 S L8
L10        1610 S L8 SSS FULL
L11             STRUCTURE UPLOADED
L12           0 S L11
L13           0 S L11 SSS FULL

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   504.20     680.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -0.73

FILE 'HCAPLUS' ENTERED AT 14:34:19 ON 30 NOV 2005
```

FILE COVERS 1907 - 30 Nov 2005 VOL 143 ISS 23
FILE LAST UPDATED: 29 Nov 2005 (20051129/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l10
L14         951 L10

=> s l14 and p/dt
       5050281 P/DT
L15         479 L14 AND P/DT

=> s l15 and py<=2002
      22790427 PY<=2002
L16         297 L15 AND PY<=2002

=> s l16 and us/pc
       1489014 US/PC
L17         223 L16 AND US/PC

=> s l17 and disease
         813039 DISEASE
         221695 DISEASES
         914619 DISEASE
                (DISEASE OR DISEASES)
L18          72 L17 AND DISEASE

=> s l18 and plasminogen
         27040 PLASMINOGEN
           175 PLASMINOGENS
         27050 PLASMINOGEN
                (PLASMINOGEN OR PLASMINOGENS)
L19           0 L18 AND PLASMINOGEN

=> d l18 ibib abs hitstr 1-10

L18  ANSWER 1 OF 72  HCAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2005:1200856  HCAPLUS
TITLE:                    Methods of treating ankylosing spondylitis using
                          anti-TNF antibodies and peptides of human tumor
                          necrosis factor
```

INVENTOR(S): Le, Junming; Vilcek, Jan T.; Daddona, Peter E.; Ghrayeb, John; Knight, David M.; Siegel, Scott A.; Shealy, David J.
PATENT ASSIGNEE(S): Centocor, Inc., USA; New York University
SOURCE: U.S. Pat. Appl. Publ., 113 pp., Cont.-in-part of U.S. Ser. No. 637,759.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 2005249735	A1	20051110	US 2004-10954	20041213	<--
US 2002132307	A1	20020919	US 2001-756161	20010108	<--
US 2003017584	A1	20030123	US 2001-756398	20010108	<--
US 6835823	B2	20041228			
US 2003049725	A1	20030313	US 2001-920137	20010801	<--
US 2002022720	A1	20020221	US 2001-927703	20010810	<--
ZA 2003001856	A	20040621	ZA 2003-1856	20030306	
US 2004120952	A1	20040624	US 2003-637759	20030808	<--

PRIORITY APPLN. INFO.:

US 2000-223360P	P	20000807
US 2000-236826P	P	20000929
US 2001-756398	A1	20010108
US 2001-920137	A2	20010801
US 2001-927703	A2	20010810
US 2003-637759	A2	20030808
US 1991-670827	B2	19910318
US 1992-853606	B2	19920318
US 1992-943852	B2	19920911
US 1993-10406	B2	19930129
US 1993-13413	B2	19930202
US 1994-192093	A2	19940204
US 1994-192102	A2	19940204
US 1994-192861	A2	19940204
US 1994-324799	A2	19941018
US 1995-570674	B3	19951211
US 1998-133119	A3	19980812

AB Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

IT INDEXING IN PROGRESS

IT **41340-25-4**, Etodolac
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of treating ankylosing spondylitis using anti-tumor necrosis factor antibodies and peptides of human tumor necrosis factor)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 2 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:77970 HCAPLUS
DOCUMENT NUMBER: 142:162653
TITLE: Transdermal delivery of low and high molecular weight drugs
INVENTOR(S): Jordan, Frederick L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 31 pp., Cont.-in-part of U.S. Ser. No. 789,836.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005019384	A1	20050127	US 2004-856567	20040528 <--
WO 2000002601	A2	20000120	WO 1999-US15409	19990708 <--
WO 2000002601	A3	20000330		
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6946144	B1	20050920	US 1999-350043	19990708 <--
US 2003064093	A1	20030403	US 2002-183764	20020625 <--
US 6759056	B2	20040706		
US 2004170676	A1	20040902	US 2004-789836	20040227 <--
WO 2005039464	A1	20050506	WO 2004-US17169	20040528
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

US 1998-92061P	P	19980708
US 1999-350043	A1	19990708
US 2002-183764	A1	20020625
US 2003-510615P	P	20031010
US 2004-789836	A2	20040227

AB A transdermal delivery system can be used to deliver high-mol. weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed. Thus, a formulation contained

acetylsalicylic acid 22 and ibuprofen 8.5 g, EtOH 500, ethoxylated macadamia nut oil 400, and water 100 mL and peppermint oil 20 drops.

IT **41340-25-4**, Etodolac
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal delivery of low and high mol. weight drugs)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 3 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1019528 HCAPLUS

DOCUMENT NUMBER: 141:428042

TITLE: Localized vaginal delivery without detrimental blood levels

INVENTOR(S): Levine, Howard L.; Bologna, William J.; De Ziegler, Dominique

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Ser. No. 510,527.
CODEN: USXXCO

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004234606	A1	20041125	US 2004-778151	20040217 <--
US 6126959	A	20001003	US 1998-145172	19980901 <--
EP 1356806	A1	20031029	EP 2003-11701	19980908
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, RO, CY				
ZA 9808328	A	19990223	ZA 1998-8328	19980911 <--
US 2002012677	A1	20020131	US 2000-510527	20000222 <--
US 6699494	B2	20040302		

PRIORITY APPLN. INFO.:

US 1997-58789P	P	19970912
US 1998-145172	A3	19980901
US 2000-510527	A2	20000222
EP 1998-943548	A3	19980908

AB The invention relates to a pharmaceutical composition for vaginal administration of a treating agent normally associated with undesired side effects at detrimental blood levels. The composition releases the treating agent at a rate to achieve local tissue concns. without such detrimental blood levels by using a therapeutically effective amount of the treating agent and a bioadhesive, cross-linked water swellable, but water-insol. polycarboxylic acid polymer. Using this composition and the method of treatment provides sufficient local levels of the drug to provide

therapeutic efficacy, but avoids many untoward adverse events. The invention also relates to a pharmaceutical composition for use during menses that includes a treating agent and a bioadhesive, cross-linked water swellable, but water-insol. polycarboxylic acid polymer. For example, pharmacokinetic study on a vaginal composition containing terbutaline and polycarbophil was found to have the extended release effect and the serum terbutaline levels were far less than the toxic level.

IT **41340-25-4**, Etodolac
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaginal delivery of drugs using crosslinked polycarboxylic acids without detrimental blood levels)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 4 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:119765 HCAPLUS

DOCUMENT NUMBER: 140:169654

TITLE: Oral pharmaceutical formulations containing alkaline agents and binders

INVENTOR(S): Kositprapa, Unchalee

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 597,206.
CODEN: USXXCO

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004028735	A1	20040212	US 2003-634321	20030804 <--
US 6096340	A	20000801	US 1997-970489	19971114 <--
US 6174548	B1	20010116	US 1998-143167	19980828 <--
US 6077541	A	20000620	US 1999-335575	19990618 <--
US 6602522	B1	20030805	US 2000-597206	20000620 <--
US 2003113376	A1	20030619	US 2002-279622	20021023 <--
US 6780435	B2	20040824		

PRIORITY APPLN. INFO.:

US 1997-970489	A3	19971114
US 1998-143167	A2	19980828
US 1999-335575	A2	19990618
US 2000-597206	A2	20000620
US 2000-607293	B1	20000630

AB An oral pharmaceutical formulation, e.g., a tablet core, contains an uncoated granule of a drug, an optional surfactant, an alkaline agent and a combination of a water-soluble binder and a water-insol. binder. The controlled release of drugs is achieved by way of the water soluble and water

insol. binders. The formulation for making granules contained: Eudragit NE30D 33.0, Plasdone K30 98.0, sodium lauryl sulfate 6.0, Avicel PH102 1439.0, felodipine 244.0, and water 1600.0 g. The granules were formed into tablets by compressing felodipine granules 160.7, glyceryl monostearate 13.5, Crospovidone 79.6, and Avicel PH101 16.2 g.

IT **41340-25-4**, Etodolac
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical formulations containing alkaline agents and binders)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 5 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:931006 HCAPLUS

DOCUMENT NUMBER: 140:737

TITLE: Modified forms of nonsteroidal antiinflammatory drugs (NSAIDs) having reduced side effects

INVENTOR(S): Lai, Ching-San; Wang, Tingmin

PATENT ASSIGNEE(S): Medinox, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 97,197.
CODEN: USXXCO

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003220468	A1	20031127	US 2003-434371	20030507 <--
US 6355666	B1	20020312	US 2000-602688	20000623 <--
US 6429223	B1	20020806	US 2000-715767	20001117 <--
US 2003088111	A1	20030508	US 2002-97197	20020312 <--

PRIORITY APPLN. INFO.:

US 2000-602688	A1	20000623
US 2000-715767	A1	20001117
US 2002-97197	A2	20020312

OTHER SOURCE(S): MARPAT 140:737

GI



I

AB Modified forms of nonsteroidal anti-inflammatory drugs (NSAIDs) are provided (preparation included). The modified NSAIDs of the invention provide a new class of antiinflammatory agent which provide the therapeutic benefits of NSAIDs while causing a much lower incidence of side-effects then typically observed with such agents. Preparation, activity, and pharmacokinetic data for a modified naproxen compound I is included.

IT **41340-25-4D**, Etodolac, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NSAID derivs. having reduced side effects, and preparation thereof)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 6 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:203395 HCAPLUS
DOCUMENT NUMBER: 138:231726
TITLE: Methods and products for treating HIV infection
INVENTOR(S): Krieg, Arthur M.; Klinman, Dennis; Steinberg, Alfred D.
PATENT ASSIGNEE(S): The University of Iowa Research Foundation, USA
SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 415,142.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003050263	A1	20030313	US 2001-931583	20010816 <--
US 6008200	A	19991228	US 1995-386063	19950207 <--
US 6194388	B1	20010227		
EP 1167377	A2	20020102	EP 2001-202811	19950207 <--
EP 1167377	A3	20040908		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1167378	A2	20020102	EP 2001-202813	19950207 <--
EP 1167378	A3	20050817		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1167379	A2	20020102	EP 2001-202814	19950207 <--
EP 1167379	A3	20040908		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 2003144184	A2	20030520	JP 2002-302338	19950207
US 2003026782	A1	20030206	US 1999-415142	19991008 <--
JP 2004024261	A2	20040129	JP 2003-178740	20030623

JP 2004043466	A2	20040212	JP 2003-178741	20030623
US 2005037985	A1	20050217	US 2003-649584	20030825 <--
JP 2004215670	A2	20040805	JP 2004-69838	20040311
PRIORITY APPLN. INFO.:			US 1994-276358	B2 19940715
			US 1995-386063	A3 19950207
			US 1999-415142	A2 19991008
			EP 1995-911630	A3 19950207
			JP 1996-504991	A3 19950207
			JP 2002-302338	A3 19950207
			US 2001-931583	B1 20010816

OTHER SOURCE(S): MARPAT 138:231726

AB Oligonucleotides containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. In particular, methods for treating HIV infection are disclosed.

IT **41340-25-4**, Etodolac
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of HIV infection using oligonucleotides containing unmethylated CpG dinucleotides by stimulating an immune response and B cells and combination with other agents)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 7 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:946115 HCAPLUS
DOCUMENT NUMBER: 138:16594
TITLE: Sustained-release analgesic compounds
INVENTOR(S): Ashton, Paul; Smith, Thomas J.; Cynkowski, Tadeusz; Cynkowska, Grazyna; Mickunas, Edmund
PATENT ASSIGNEE(S): Control Delivery Systems, USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002098427	A2	20021212	WO 2002-US17613	20020605 <--
WO 2002098427	A3	20030220		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2448665	AA	20021212	CA 2002-2448665		20020605 <--
US 2003022876	A1	20030130	US 2002-162216		20020605 <--
NZ 529661	A	20031219	NZ 2002-529661		20020605
EP 1399161	A2	20040324	EP 2002-734669		20020605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2002010179	A	20040427	BR 2002-10179		20020605
CN 1514729	A	20040721	CN 2002-811420		20020605
JP 2004536811	T2	20041209	JP 2003-501466		20020605
PRIORITY APPLN. INFO.:			US 2001-295556P	P	20010605
			WO 2002-US17613	W	20020605

OTHER SOURCE(S): MARPAT 138:16594

AB A pharmaceutically active inventive compound comprises two independently active analgesic moieties covalently conjoined through a physiol. labile linker. A preferred embodiment comprises an opioid, such as morphine, covalently linked to at least one analgesic compound selected from the group consisting of an opioid or a no-opioid compound through a physiol. labile linker. Suitable covalent linkers are covalently bonded to the two independently active analgesic compds. through one or more lactone, lactam, or sulfonamido linkages. Suitable linkers include endogenous carboxylate, amido, and sulfonamido moieties, and exogenous moieties that form the aforementioned lactone, lactam or sulfonamido linkages.

IT **41340-25-4DP**, Etodolac, conjugates with analgesics
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(sustained-release analgesic compds.)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 8 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:832601 HCAPLUS

DOCUMENT NUMBER: 137:333142

TITLE: Use of NSAIDS for prevention and treatment of cellular abnormalities of the lung or bronchial pathway

INVENTOR(S): Eisen, Drore; Herlands, Louis; Prior, Christopher P.

PATENT ASSIGNEE(S): Oraltech Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085342	A2	20021031	WO 2002-US12321	20020418 <--
WO 2002085342	A3	20040115		

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003004142	A1	20030102	US 2002-124893	20020417 <--
PRIORITY APPLN. INFO.:			US 2001-284731P	P 20010418

AB The invention is directed to uses of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment and prevention of cellular abnormalities of the lung or bronchial pathway. The NSAIDs may be COX inhibitors. Formulations such as aerosolized sprays are described.

IT **41340-25-4**, Etodolac
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NSAIDS for prevention and treatment of cellular abnormalities of the lung or bronchial pathway)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 9 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:832592 HCAPLUS

DOCUMENT NUMBER: 137:333141

TITLE: Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract

INVENTOR(S): Prior, Christopher P.; Eisen, Drore; Herlands, Louis

PATENT ASSIGNEE(S): Oraltech Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085327	A2	20021031	WO 2002-US12702	20020418 <--
WO 2002085327	A3	20021219		

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003004143 A1 20030102 US 2002-125218 20020418 <--

PRIORITY APPLN. INFO.: US 2001-284756P P 20010418

AB The invention is directed to uses of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment and prevention of cellular abnormalities of female reproductive tract. The NSAIDs may be COX inhibitors. Formulations are described.

IT **41340-25-4**, Etodolac

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (NSAIDS for prevention and treatment of cellular abnormalities of the female reproductive tract)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 10 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:777648 HCAPLUS

DOCUMENT NUMBER: 137:257659

TITLE: Therapeutic combinations for cardiovascular and inflammatory indications

INVENTOR(S): Seibert, Karen; Keller, Bradley T.; Isakson, Peter C.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078625	A2	20021010	WO 2002-US9185	20020327 <--
WO 2002078625	A3	20030313		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003199482	A1	20031023	US 2002-107809	20020328 <--
CN 1527709	A	20040908	CN 2002-810210	20020328

PRIORITY APPLN. INFO.: US 2001-279239P P 20010328

AB The invention provides therapeutic combinations and methods for treating

or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic combination comprises an Apical Sodium codependent Bile acid Transport (ASBT) inhibitor combined with COX-2 inhibitor. A further therapeutic combination comprises an ASBT inhibitor, a COX-2 inhibitor and an HMG Co-A reductase inhibitor. Another therapeutic combination comprises a chromene COX-2 inhibitor and an HMG Co-A reductase inhibitor.

IT **41340-25-4**, Etodolac
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG CoA reductase, cyclooxygenase and sodium codependent bile acid transport inhibitors for cardiovascular and inflammatory **diseases** in humans)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



=> d l18 ibib abs hitstr 11-25

L18 ANSWER 11 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:754159 HCAPLUS
DOCUMENT NUMBER: 137:263297
TITLE: Preparation of 2,7-diamino-5-heptenoic acid derivatives for the treatment of cancer
INVENTOR(S): Manning, Pamela T.; Connor, Jane R.; Seibert, Karen; Rao, Chinthalapally V.; Reddy, Bandaru S.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 295 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076395	A2	20021003	WO 2002-US8938	20020321 <--
WO 2002076395	A3	20040812		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,

GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003013702	A1	20030116	US 2001-961969		20010924 <--
CA 2441394	AA	20021003	CA 2002-2441394		20020321 <--
EP 1463495	A2	20041006	EP 2002-717708		20020321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2005500259	T2	20050106	JP 2002-574911		20020321
PRIORITY APPLN. INFO.:			US 2001-278512P	P	20010323
			US 2001-961969	A	20010924
			WO 2002-US8938	W	20020321

OTHER SOURCE(S): MARPAT 137:263297

AB Agents and methods for chemoprevention and treatment of neoplasia are described, the agents including a selective inhibitor of inducible nitric oxide synthase and a combination of a selective inhibitor of inducible nitric oxide synthase and an inhibitor of cyclooxygenase-2 in a pharmaceutical composition 2,7-Diamino-5-heptenoic acid derivs. R7N:CMeNHCH2CR1:CR2CH2CH2CH(NH2)C(O)J [R1, R2 = H, halo, alkyl, haloalkyl (at least one of R1 or R2 contains halogen); R7 = H, OH; J = OH, alkoxy, NR3R4, where R3 = H, alkyl, alkenyl, alkynyl and R4 = H, (un)substituted heterocyclyl] or their pharmaceutically-acceptable salts are among the compds. claimed. Thus, (2S,5E)-2-amino-6-fluoro-7-[(1-iminoethyl)amino]-5-heptenoic acid dihydrochloride was prepared by a multistep procedure starting from L-glutamic acid and showed IC50 values 0.36, 68, 3.6, and 0.1 μM in hiNOS, hecNOS, hncNOS, and human cartilage assays, resp.

IT **41340-25-4**, Etodolac
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of diaminoheptenoic acid derivs. for treatment of cancer)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 12 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:696670 HCAPLUS

DOCUMENT NUMBER: 137:210976

TITLE: Prevention and treatment of Alzheimer's **disease** with Aβ42 lowering agents

INVENTOR(S): Koo, Edward Hao Mang; Golde, Todd Eliot; Galasko, Douglas Roger

PATENT ASSIGNEE(S): Mayo Foundation For Medical Education and Research, USA; The Regents of The University of California

SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of Appl. No. PCTUS/01/11956.
CODEN: USXXCO

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002128319	A1	20020912	US 2001-12606	20011207 <--
US 6911466	B2	20050628		
WO 2001078721	A1	20011025	WO 2001-US11956	20010412 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2005089945	A1	20050428	US 2004-928925	20040827 <--
US 2005186559	A1	20050825	US 2005-113789	20050425 <--
PRIORITY APPLN. INFO.:			US 2000-196617P	P 20000413
			WO 2001-US11956	A2 20010412
			US 2001-12606	A3 20011207

AB The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's **disease** by administering an Aβ42 lowering agent to a mammal under conditions in which levels of Aβ42 are selectively reduced, levels of Aβ38 are increased, and levels of Aβ40 are unchanged. The invention provides methods and materials for developing and identifying Aβ42 lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's **disease.** The invention also provides compns. of Aβ42 lowering agents and antioxidants, Aβ42 lowering agents and non-selective secretase inhibitors, as well as Aβ42 lowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβ42 lowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβ42 lowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.

IT **41340-25-4**, Etodolac
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prevention and treatment of Alzheimer's **disease** with Aβ42 lowering agents)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 13 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:695781 HCAPLUS
DOCUMENT NUMBER: 137:210955
TITLE: New use of pharmaceutically active compounds for

prevention and treatment of gastric ulcer
INVENTOR(S): Eek, Arne
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069968	A1	20020912	WO 2002-SE375	20020305 <--
WO 2002069968	C1	20030417		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN; CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440100	AA	20020912	CA 2002-2440100	20020305 <--
EE 200300434	A	20031215	EE 2003-434	20020305
EP 1370261	A2	20031217	EP 2002-701851	20020305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1496259	A	20040512	CN 2002-806109	20020305
BR 2002007762	A	20040601	BR 2002-7762	20020305
JP 2004520422	T2	20040708	JP 2002-569143	20020305
ZA 2003006611	A	20041125	ZA 2003-6611	20030825
BG 108144	A	20040930	BG 2003-108144	20030901
NO 2003003919	A	20030904	NO 2003-3919	20030904
US 2004082605	A1	20040429	US 2003-469906	20030905 <--

PRIORITY APPLN. INFO.:

SE 2001-798	A	20010308
SE 2001-3291	A	20011003
WO 2002-SE375	W	20020305

OTHER SOURCE(S): MARPAT 137:210955

AB The present invention relates to a new use of certain pharmaceutically active compds. in the treatment and/or prevention of medicament induced gastric ulcer. More particularly the invention is directed to the use of said compds., and pharmaceutically acceptable salts thereof, for the treatment and/or prevention of NSAID (non-steroidal antiinflammatory drugs) induced gastric ulcer as well as a pharmaceutical composition in the unit dosage form for the prevention of NSAID induced gastric ulcer in a mammal comprising an NSAID together with a 6-carboxamido-imidazo[1,2-a]pyridine compds. Other pharmaceutically active compds. used in the present invention comprises COX-2 inhibitors, NO-NSAIDs and bisphosphonates.

IT **41340-25-4**, Etodolac
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (pharmaceutically active compds. for prevention and treatment of gastric ulcer)

RN 41340-25-4 HCAPLUS
CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 14 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:595343 HCAPLUS
DOCUMENT NUMBER: 137:150228
TITLE: Antiinflammatory compositions and methods for therapy through enhanced tissue regeneration
INVENTOR(S): Uhrich, Kathryn E.; Macedo, Braz
PATENT ASSIGNEE(S): Rutgers, The State University of New Jersey, USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002106345	A1	20020808	US 2000-732516		20001207 <--
US 6685928	B2	20040203			
PRIORITY APPLN. INFO.:			US 1999-304190P	P	19991207
			US 1999-455861	A	19991207

AB The invention provides methods of promoting healing through enhanced regeneration of tissue (e.g. hard tissue or soft tissue) by contacting the tissue or the surrounding tissue with an antiinflammatory agent, preferably in a controlled-release form, e.g. by dispersing the agent through a polymer matrix, appending the agent to a polymer backbone, or incorporating the agent directly into a biodegradable polymer backbone. These methods are useful in a variety of dental and orthopedic applications. Expts. are presented which demonstrate that implantation of a film comprising an aromatic polyanhydride that hydrolyzes to form a therapeutically useful salicylate resulted in less swelling in tissues adjacent to the film and a decrease in the d. of inflammatory cells as compared to other polyanhydride films. Preparation of e.g. poly[1,6-bis(o-carboxyphenoxy) hexane] is described.

IT **41340-25-4**, Etodolac **41340-25-4D**, Etodolac, polymer backbone-incorporated
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory compns. and methods for therapy through enhanced tissue regeneration)
RN 41340-25-4 HCAPLUS
CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 41340-25-4 HCAPLUS
CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 15 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:588980 HCAPLUS
DOCUMENT NUMBER: 137:135080
TITLE: Modification of NSAIDs by sulfur-containing functional groups
INVENTOR(S): Lai, Ching-San; Wang, Tingmin
PATENT ASSIGNEE(S): Medinox, Inc., USA
SOURCE: U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 602,688.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6429223	B1	20020806	US 2000-715767	20001117 <--
US 6355666	B1	20020312	US 2000-602688	20000623 <--
CA 2414150	AA	20020103	CA 2001-2414150	20010619 <--
WO 2002000167	A2	20020103	WO 2001-US19750	20010619 <--
WO 2002000167	A3	20020404		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001070010	A5	20020108	AU 2001-70010	20010619 <--
EP 1296929	A2	20030402	EP 2001-948537	20010619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

JP 2004517037	T2	20040610	JP 2002-504950	20010619
US 2003220468	A1	20031127	US 2003-434371	20030507 <--
PRIORITY APPLN. INFO.:			US 2000-602688	A2 20000623
			US 2000-715767	A 20001117
			WO 2001-US19750	W 20010619
			US 2002-97197	A2 20020312

AB A method for the alleviation of side effects induced by the administration of a nonsteroidal anti-inflammatory drug (NSAID) to a subject comprises chemical modifying the NSAID by covalent attachment of a sulfur-containing functional group, such as sulfoxide, sulfonate, reverse sulfonate, sulfonamide, reverse sulfonamide, sulfone, sulfinate, or reverse sulfinate to provide prodrugs. The maximum blood concentration (Cmax) of the prodrug is reduced relative to the unmodified NSAID by about 10-90%. For example, oral administration of a naproxen prodrug, i.e., a conjugate of naproxen and tosylate (preparation given), resulted in the release of free naproxen. In rats, the prodrug had equivalent pharmacol. efficacy and greatly improved gastrointestinal safety profile compared to naproxen.

IT **41340-25-4**, Etodolac
RL: ADV (Adverse effect, including toxicity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(prodrugs of NSAIDs containing sulfur-containing functional groups for alleviation of side effects during therapy)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 16 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:449662 HCAPLUS
DOCUMENT NUMBER: 137:33310
TITLE: Preparation of anilinopyrimidines as IKK inhibitors
INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046171	A2	20020613	WO 2001-US46403	20011205 <--
WO 2002046171	A3	20030123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003203926	A1	20031030	US 2001-4642		20011204 <--
CA 2431160	AA	20020613	CA 2001-2431160		20011205 <--
AU 2002020195	A5	20020618	AU 2002-20195		20011205 <--
EP 1349841	A2	20031008	EP 2001-999564		20011205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004523497	T2	20040805	JP 2002-547910		20011205
PRIORITY APPLN. INFO.:			US 2000-251816P	P	20001206
			WO 2001-US46403	W	20011205

OTHER SOURCE(S): MARPAT 137:33310
GI



I

AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of IKK, particularly IKK-2, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of ≤ 1 μM in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds.

IT **41340-25-4**, Etodolac
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory agent; preparation of anilinopyrimidines as IKK inhibitors)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 17 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:425331 HCAPLUS
DOCUMENT NUMBER: 136:395959
TITLE: Antiinflammatory/analgesic method and topical composition including penetration enhancers to treat musculoskeletal disorders
INVENTOR(S): Petrus, Edward J.
PATENT ASSIGNEE(S): Advanced Medical Instruments, USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6399093	B1	20020604	US 1999-314829	19990519 <--
PRIORITY APPLN. INFO.:			US 1999-314829	19990519

AB A method and composition are disclosed for the treatment of musculoskeletal disorders in mammals by the application of a topical composition comprising a permeation enhancing amount of one or more penetration enhancers, and one or more bio-affecting agents to provide anti-inflammatory relief and analgesia to the applied body part.

IT **41340-25-4**, Etodolac
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory/analgesic method and topical composition including penetration enhancers to treat musculoskeletal disorders)

RN 41340-25-4 HCAPLUS
CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 82 THERE ARE 82 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 18 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:107912 HCAPLUS

DOCUMENT NUMBER: 136:161383
TITLE: Compositions and methods for the treatment of neurodegenerative **diseases**
INVENTOR(S): Hellberg, Mark R.; Nixon, Jon C.; York, Billie M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002016359	A1	20020207	US 2001-862132		20010521 <--
PRIORITY APPLN. INFO.:			US 2000-214902P	P	20000629

OTHER SOURCE(S): MARPAT 136:161383

AB Methods are disclosed for the treatment of neurodegenerative **diseases** and disorders. The methods utilize compns. containing agent of formula [A-X=NSAIA containing carboxylic acid; A-X=an ester or amide linkage derived from the carboxylic acid moiety of the NSAIA; X=O or NR; R=H, C1-C6 alkyl or C3-C6 cycloalkyl; Y, if present, is O, NR, C(R)2, CH(OH) or S(O)n; n is 2 to 4 and m is 1 to 4 when Y is O, NR, or S(O)n; n is 0 to 4 and m is 0 to 4 when Y is C(R)2 or is not present; n is 1-4 and m is 0 to 4 when Y is CH(OH); n' is 0 to 2; and Z is substituted dihydrobenzofuranyl, substituted dihydrobenzopyranyl or substituted dichloronaphtopyranyl] having an antiinflammatory and antioxidant moiety covalently linked by an amide or ester bond.

IT **41340-25-4**, Etodolic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for the treatment of neurodegenerative **diseases**)
RN 41340-25-4 HCAPLUS
CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 19 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:89826 HCAPLUS
DOCUMENT NUMBER: 136:129055
TITLE: Method using a cyclooxygenase 2 (COX-2) inhibitor for treatment of an immunodeficiency condition
INVENTOR(S): Tasken, Kjetil; Moutschen, Michel; Rahmouni-Piette, Souad; Aandahl, Einar Martin; Aukrust, Pal; Froland, Stig S.; Johansson, Christian Carl; Hansson, Vidar; Klaveness, Jo
PATENT ASSIGNEE(S): Lauras AS, Norway; Jones, Elizabeth Louise
SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002007721	A2	20020131	WO 2001-GB3284	20010720 <--
WO 2002007721	A3	20020418		
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2415577	AA	20020131	CA 2001-2415577	20010720 <--
EP 1303265	A2	20030423	EP 2001-949787	20010720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 524252	A	20040326	NZ 2001-524252	20010720
JP 2004510705	T2	20040408	JP 2002-513457	20010720
ZA 2003000446	A	20040416	ZA 2003-446	20030116
NO 2003000276	A	20030318	NO 2003-276	20030120
US 2004082640	A1	20040429	US 2003-333657	20030606 <--

PRIORITY APPLN. INFO.:		
	GB 2000-17908	A 20000720
	GB 2001-9648	A 20010419
	WO 2001-GB3284	W 20010720

OTHER SOURCE(S): MARPAT 136:129055

AB The invention provides a method of treating or preventing a disorder typified by an immunodeficiency (e.g. HIV), wherein the patient is administered a COX-2 inhibitor or derivative or pharmaceutically acceptable salt thereof, preferably diisopropylfluorophosphate, L-745337, rofecoxib, NS 398, SC 58125, etodolac, meloxicam, celecoxib or nimesulide, as well as compns. and products containing the same or use of the same in preparing medicaments and for treatment.

IT **41340-25-4**, Etodolac
RL: AGR (Agricultural use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase 2 inhibitor for immunodeficiency condition treatment)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 20 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:71873 HCAPLUS
DOCUMENT NUMBER: 136:123671
TITLE: Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
INVENTOR(S): Kararli, Tugrul T.; Bandyopadhyay, Rebanta; Singh, Satish K.; Hawley, Leslie C.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005815	A1	20020124	WO 2001-US22061	20010712 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2414780	AA	20020124	CA 2001-2414780	20010712 <--
AU 2001075908	A5	20020130	AU 2001-75908	20010712 <--
US 2002035264	A1	20020321	US 2001-904098	20010712 <--
EP 1303271	A1	20030423	EP 2001-953462	20010712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004528267	T2	20040916	JP 2002-511747	20010712
ZA 2003009298	A	20040512	ZA 2003-9298	20031128

PRIORITY APPLN. INFO.:		
US 2000-218101P	P	20000713
US 2001-279285P	P	20010328
US 2001-294838P	P	20010531
US 2001-296388P	P	20010606
WO 2001-US22061	W	20010712

OTHER SOURCE(S): MARPAT 136:123671

AB A pharmaceutical composition suitable for topical administration to an eye contains a selective COX-2 inhibitor or nanoparticles of a drug of low water solubility, at a concentration effective for the treatment and/or prophylaxis of a disorder in the eye, and 1 or more ophthalmically acceptable excipients that reduce rate of removal from the eye such that the composition has an effective residence time of 2-24 h. Also provided is a method of treating and/or preventing a disorder in an eye, the method comprising administering to the eye a composition of the invention. Thus, an ophthalmic nanoparticle suspension contained valdecoxib at 2.15 mg/g, 1.2% glycerin, 0.8% EDTA disodium salt, 4.0% Gelcarin GP-379NF, 0.21% SeaSpen PF and 0.82% Povidone.

IT **41340-25-4**, Etodolac
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ophthalmic formulation of cyclooxygenase-2 inhibitor pharmaceuticals)
RN 41340-25-4 HCAPLUS
CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 21 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:10229 HCAPLUS
DOCUMENT NUMBER: 136:85672
TITLE: Modified forms of pharmacologically active agents for use as nonsteroidal anti-inflammatory drugs (NSAIDs)
INVENTOR(S): Lai, Ching-san; Wang, Tingmin
PATENT ASSIGNEE(S): Medinox, Inc., USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000167	A2	20020103	WO 2001-US19750	20010619 <--
WO 2002000167	A3	20020404		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6355666	B1	20020312	US 2000-602688	20000623 <--
US 6429223	B1	20020806	US 2000-715767	20001117 <--
CA 2414150	AA	20020103	CA 2001-2414150	20010619 <--
AU 2001070010	A5	20020108	AU 2001-70010	20010619 <--
EP 1296929	A2	20030402	EP 2001-948537	20010619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517037	T2	20040610	JP 2002-504950	20010619

PRIORITY APPLN. INFO.:

US 2000-602688	A1	20000623
US 2000-715767	A1	20001117
WO 2001-US19750	W	20010619

OTHER SOURCE(S): MARPAT 136:85672
GI



I

AB In accordance with the present invention, there are provided modified forms of nonsteroidal anti-inflammatory drugs (NSAIDs), X-L-Z [X = non-steroidal anti-inflammatory drug (NSAID); L = optional linker/spacer, WR; Z = sulfur-containing functional group containing an (un)substituted hydrocarbon; R = (un)substituted alkylene, cycloalkylene, heterpcyclic, oxyalkylene, alkenylene, arylene, alkarylene; W = ester, reverse ester, thioester, reverse thioester, amide, reverse amide, phosphate, phosphonate, imine, enamine]. Thus, naproxen (I; R = H) was esterified with propane-1,3-diol in CHCl3 containing catalytic p-tosic acid followed by sulfonation with tosyl chloride in pyridine to give prodrug I [R = (CH2)3OSO2C4H4Me-4 (II)]. Modified NSAIDs according to the invention provide a new class of anti-inflammatory agent which provides the therapeutic benefits of NSAIDs while causing a much lower incidence of side-effects then typically observed with such agents. Thus, prodrug II substantially reduced GI toxicity (15% that of naproxen) while maintaining efficacy in anti-inflammation activity in both acute and chronic inflammation in animal models [e.g., rat carrageenan-induced hindlimb edema, P = 0.78 ± 0.04 (4 h) and P = 0.93 ± 0.04 (5 h)].

IT **41340-25-4DP**, Etodolac, modified prodrug
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(modification of pharmacol. active agents for use as nonsteroidal anti-inflammatory drugs)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 22 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:780679 HCAPLUS
DOCUMENT NUMBER: 135:327362
TITLE: Nonsteroidal antiinflammatory drug (NSAID) and NSAID derivative amyloid Aβ42 polypeptide-lowering agents for the treatment of Alzheimer's **disease**, and screening methods
INVENTOR(S): Koo, Edward Hao Mang; Golde, Todd Eliot; Galasko, Douglas Roger
PATENT ASSIGNEE(S): Mayo Foundation for Medical Education and Research, USA

SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078721	A1	20011025	WO 2001-US11956	20010412 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2406383	AA	20011025	CA 2001-2406383	20010412 <--
AU 2001057022	A5	20011030	AU 2001-57022	20010412 <--
EP 1284729	A1	20030226	EP 2001-930491	20010412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003530437	T2	20031014	JP 2001-576021	20010412
US 2002128319	A1	20020912	US 2001-12606	20011207 <--
US 6911466	B2	20050628		
US 2005089945	A1	20050428	US 2004-928925	20040827 <--
US 2005186559	A1	20050825	US 2005-113789	20050425 <--

PRIORITY APPLN. INFO.:			
US 2000-196617P	P	20000413	
WO 2001-US11956	W	20010412	
US 2001-12606	A3	20011207	

AB A method is provided for preventing, delaying, or reversing the progression of Alzheimer's **disease** by administering an Aβ42-lowering agent to a mammal under conditions in which levels of Aβ42 are selectively reduced, levels of Aβ38 are increased, and levels of Aβ40 are unchanged. The invention provides methods and materials for developing and identifying Aβ42-lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's **disease.** The invention also provides compns. of Aβ42-lowering agents and antioxidants, Aβ42 lowering agents and non-selective secretase inhibitors, and Aβ42 lowering agents and acetylcholinesterase inhibitors. The invention further provides kits containing Aβ42-lowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβ42-lowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors. The agents of the invention include nonsteroidal antiinflammatory drugs (NSAIDs) and NSAID derivs.

IT **41340-25-4**, Etodolac
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(NSAID and NSAID derivative amyloid Aβ42 polypeptide-lowering agents for treatment of Alzheimer's **disease**, and screening methods)

RN 41340-25-4 HCAPLUS
CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 23 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:693651 HCAPLUS
DOCUMENT NUMBER: 135:240908
TITLE: Assay for agents that induce chemokinesis
INVENTOR(S): Carson, Dennis A.; Leoni, Lorenzo M.; Cottam, Howard B.
PATENT ASSIGNEE(S): Regents of the University of California, USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001069240	A1	20010920	WO 2001-US8581	20010316 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2402908	AA	20010920	CA 2001-2402908	20010316 <--
US 2002010125	A1	20020124	US 2001-810010	20010316 <--
EP 1269183	A1	20030102	EP 2001-920474	20010316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003527603	T2	20030916	JP 2001-568069	20010316
PRIORITY APPLN. INFO.:			US 2000-189976P	P 20000316
			WO 2001-US8581	W 20010316

AB The present invention provides methods for identifying compds. that can induce cellular chemokinesis. According to the present invention, chemokinesis interferes with immune and inflammatory responses by increasing cell movements and altering cell migration patterns. Surprisingly, compds. isolated according to the present invention can interfere with the spread of malignant cells through the body, reduce inflammatory responses and can cause leukocytes to be retained in lymph nodes, the spleen and other organs of the reticulo-endothelial system. Several methods are contemplated by the present invention for identifying compds. which can induce chemokinesis. In one embodiment the method involves contacting a population of target cells with a test compound and observing whether the target cells produce a chemotactic mol.; wherein the

target cell has a cognate receptor for the chemotactic mol. In another embodiment, the method involves contacting a population of target cells with a test compound and observing whether the targets cells homotypically aggregate. In yet another embodiment, the method involves contacting a population of target cells with a test compound and observing whether actin filaments in the target cells form stress fibers.

IT **41340-25-4**, Etodolac
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(assay for chemokinesis-inducing agents and agent use for interference with immune and inflammatory responses for inhibition of cancer and transplant rejection and autoimmunity and other **diseases**)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 24 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:666685 HCAPLUS
DOCUMENT NUMBER: 135:231699
TITLE: Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
INVENTOR(S): Ouali, Aomar; Azad, Abul Kalam
PATENT ASSIGNEE(S): Pharmascience Inc., Can.
SOURCE: U.S., 8 pp., Cont.-in-part of U.S. 6,183,779.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6287600	B1	20010911	US 2000-528550	20000320 <--
US 6183779	B1	20010206	US 1999-273692	19990322 <--
CA 2301378	AA	20000922	CA 2000-2301378	20000320 <--
CA 2301378	C	20000922		

PRIORITY APPLN. INFO.: US 1999-273692 A2 19990322

AB A pharmaceutical composition is provided for the oral administration of an NSAID and a prostaglandin. The composition is a solid dosage form wherein the NSAID is enterically coated and the prostaglandin is present along with an effective stabilizing amount of a prostaglandin stabilizing agent such as hydroxypropyl methylcellulose or polyvinylpyrrolidone. Exemplary dosage forms are bilayer tablets in which the prostaglandin is misoprostol and the NSAID is diclofenac, piroxicam, or a pharmaceutically acceptable salt

thereof. Methods for using the composition to treat NSAID-responsive conditions, disorders and **diseases** are provided as well. A 1% misoprostol-hydroxypropyl methylcellulose complex was made by mixing misoprostol with HPMC in a ratio of 1:99. Granules contained 1% misoprostol-HPMC complex 20.0, crospovidone XL 8.0, microcryst. cellulose PH102 170.8, hydrogenated castor oil powder 0.8, and colloidal silicon dioxide 0.4 mg. A blend of enterically coated granules contained diclofenac sodium 50.0, lactose 15.0, microcryst. cellulose PH102 114.0, starch 9.0, povidone PVK-30 4.0, methacrylic acid copolymer 5.4, triacetin 0.54, antifoam 1520-US 0.06, and hydrogenated castor oil powder 2 mg. A bilayer tablet was prepared containing above misoprostol solid dispersion and enterically coated granules of diclofenac.

IT **41340-25-4**, Etodolac
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilized pharmaceutical composition of nonsteroidal anti-inflammatory agent and prostaglandin)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 25 OF 72 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:434854 HCAPLUS
DOCUMENT NUMBER: 135:51045
TITLE: Therapeutic compositions containing anti-inflammatory agents and biodegradable polyanhydrides
INVENTOR(S): Uhrich, Kathryn; Macedo, Braz
PATENT ASSIGNEE(S): Rutgers, the State University of New Jersey, USA; University of Medicine and Dentistry
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041753	A2	20010614	WO 2000-US33378	20001207 <--
WO 2001041753	A3	20020912		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2393676	AA	20010614	CA 2000-2393676		20001207 <--
EP 1261347	A1	20021204	EP 2000-982544		20001207 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2003528044	T2	20030924	JP 2001-543098		20001207
US 2004038948	A1	20040226	US 2003-368288		20030218 <--
PRIORITY APPLN. INFO.:			US 1999-455861	A	19991207
			US 1999-304190P	P	19991207
			WO 2000-US33378	W	20001207
			US 2002-165220	B1	20020607

AB Methods of promoting healing through enhanced regeneration of tissue (e.g. hard tissue or soft tissue) by contacting the tissue or the surrounding tissue with an antiinflammatory agent are useful in a variety of dental and orthopedic applications. Thus, poly[1,6-bis(o-carboxyphenoxy)hexane] was prepared in a series of steps by the treatment of salicylic acid with 1,6-dibromohexane, and polymerization of the resulting 1,6-bis(o-carboxyphenoxy)hexane. The polymer was characterized by glass transition temperature measurements and then subjected to compression molding.

IT **41340-25-4**, Etodolac
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. containing antiinflammatory agents and biodegradable polyanhydrides)

RN 41340-25-4 HCAPLUS

CN Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	138.20	819.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-18.25	-18.98

STN INTERNATIONAL LOGOFF AT 14:37:54 ON 30 NOV 2005